MORGANTOWN, W.Va. – The WVU Cancer Institute is enrolling patients in an innovative clinical trial to treat ovarian cancer.
Valerie Galvan Turner, M.D., gynecologic oncologist at the WVU Cancer Institute, will help lead the trial to evaluate the efficacy of varying dosages and combinations of the cancer medications pegylated liposomal doxorubicin (PLD), atezolizumab, and bevacizumab in the treatment of ovarian cancer.
“We are excited to bring this clinical trial to West Virginia and the WVU Cancer Institute,” Dr. Galvan Turner said. “This treatment has the potential to allow for more options for patients for whom other treatments may not be effective.”
The clinical trial is open to epithelial ovarian cancer patients whose cancer recurred less than one year after completing their first treatment or line of chemotherapy and are considered platinum resistant.
All participants will receive treatment, but the types of treatment will be randomly assigned.
“The WVU Cancer Institute is dedicated to expanding the field of knowledge of cancer treatment,” Galvan Turner said. “We hope this study will help advance the field and provide more options for patients with ovarian cancer.”
WVU Medicine Grateful Patients program provides $10K to help West Virginians plan for end-of-life care
The Grateful Patients, Families, and Friends program recently contributed $10,000 to ensure the West Virginia Center for End-of-Life Care can continue to provide free information, education and resources to help West Virginians document their wishes for medical care.
Chad Morley, M.D., WVU Medicine urologist, has been recognized for excellence in performing GreenLight™ laser therapy treatment – a minimally invasive outpatient procedure to treat benign prostatic hyperplasia (BPH), which can relieve bothersome voiding symptoms. Dr. Morley is the first urologist in the state to receive this honor.
Specialists from WVU Medicine Children’s are now providing appointments for families at WVU Medicine St. Joseph’s Hospital in Buckhannon.